Search

Your search keyword '"Zent, Clive"' showing total 1,004 results

Search Constraints

Start Over You searched for: Author "Zent, Clive" Remove constraint Author: "Zent, Clive"
1,004 results on '"Zent, Clive"'

Search Results

1. Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

8. Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia

9. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

10. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

14. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

16. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms

19. First dose infusion reaction during anti-CD20 monoclonal antibody therapy in chronic lymphocytic leukemia associates with high IP-10 levels amid cytokine release syndrome

21. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

22. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

24. Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis

29. Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

30. Corrigendum to “Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia” [Leuk. Res. 120 (2022) 106919]

31. Development of a distributed international patient data registry for hairy cell leukemia

33. Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.

39. The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

41. Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

42. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)

48. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis

Catalog

Books, media, physical & digital resources